Biotech

Biotech narratives get much clearer when the team separates platform ambition from program evidence. The public resources that help most are the ones that connect translational milestones, clinical operations, and regulatory planning instead of letting each discipline pretend it can work alone.

Three signals I would keep in view:
- Biotech strategy gets stronger when teams separate platform promise from program evidence.
- Clinical planning works best when operational realities shape the science plan early.
- Regulatory readiness is easier when evidence packages are built incrementally instead of backwards.

Read first:
- FDA drug development and approval process: fda.gov/drugs/development-approval-process-drugs
A grounding document for the path from development to review and approval.
- NCATS translational science spectrum: ncats.nih.gov/translation/spectrum
Useful for keeping research work tied to concrete translational stages.

Documents worth saving:
- Addgene protocols: addgene.org/protocols/
Practical wet-lab documentation that is genuinely useful for day-to-day work.
- NCBI Bookshelf: ncbi.nlm.nih.gov/books/
A deep public archive for primers, reference texts, and method overviews.

Watch next:
- NIH video archive: youtube.com/@NIH/videos
Webinars and talks that help keep the science connected to real public research practice.

If this post is useful, the next contribution should add a real example, a worked document, or a failure case someone else can learn from.

The signals I care about are reproducibility of the evidence package, time from milestone to next decision, and readiness for study startup or scale-up. Those metrics reveal whether a team is generating knowledge or only generating slides.

Three metrics worth pressure-testing:
- quality and reproducibility of program evidence
- speed from milestone completion to next decision point
- operational readiness for study startup or expansion

Source material behind the scorecard:
- FDA drug development and approval process: fda.gov/drugs/development-approval-process-drugs
A grounding document for the path from development to review and approval.
- scverse: scverse.org/
A strong starting point for open computational work in modern omics analysis.

If your team has a sharper dashboard, share the metric definitions and the decisions they actually change. That is what makes numbers reusable.

FDA and NIH material give the operating frame; scverse and related open tooling show how modern analysis work is actually being done. That combination is useful because it keeps the science and the operational path in the same conversation.

The stack categories worth comparing here:
- literature and prior-art discovery tools
- clinical operations planning systems
- regulatory and documentation workflows

Open materials worth opening side by side:
- scvi-tools: github.com/scverse/scvi-tools
Open source probabilistic tooling for single-cell and spatial omics work.
- Biopython: github.com/biopython/biopython
Still useful as a practical reminder that a lot of bio tooling is public and inspectable.
- FDA drug development and approval process: fda.gov/drugs/development-approval-process-drugs
A grounding document for the path from development to review and approval.

Working documents and guides:
- Addgene protocols: addgene.org/protocols/
Practical wet-lab documentation that is genuinely useful for day-to-day work.
- NCBI Bookshelf: ncbi.nlm.nih.gov/books/
A deep public archive for primers, reference texts, and method overviews.

Program milestone map:

## Program map

- hypothesis:
- lead indication:
- key preclinical readout:
- translational bridge:
- regulatory question to answer next:
- financing or partnering milestone unlocked by this package:

A healthy workflow names the program hypothesis, maps preclinical and translational milestones to the next financing or partnering decision, and then builds clinical and regulatory readiness in parallel. The work gets expensive when those streams only meet at the deadline.

A sequence I would actually hand to a teammate:
1. Clarify whether the value is in the platform, the lead program, or the operating model.
2. Map preclinical and translational milestones to the next financing or partnering decision.
3. Build trial operations and regulatory preparation in parallel with scientific execution.

Useful operating references:
- NCATS translational science spectrum: ncats.nih.gov/translation/spectrum
Useful for keeping research work tied to concrete translational stages.
- scvi-tools: github.com/scverse/scvi-tools
Open source probabilistic tooling for single-cell and spatial omics work.

If your team has a better workflow, post it with the context around team size, constraints, and exactly where the process tends to break.